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ABSTRACT
The aim of this study is to evaluate the requirements for marketing authorization procedures of new drugs, generic medicines in developed countries 
such as Europe and to compare these procedures with those in developing countries such as Zimbabwe. Medicines control authority of Zimbabwe 
(MCAZ) grants the marketing authorization for medicinal products in Zimbabwe. However, there are still some gaps which need to be filled by the 
MCAZ to reach other bigger markets in the world. A comparative study of current MCAZ regulatory administration and practices with those of 
stringent regulators such as European Union will assist in the identification of these loopholes. It also provides the need for improvement with regard 
to pharmaceutical industries compliance with the relevant standards. This study will give a tremendous reassurance that the MCAZ regulatory affairs 
acquiescence is being met and gap analysis will systematically challenge the MCAZ regulatory requirements and procedures by comparing them to 
the European medicines agency regulatory guidelines, which will provide MCAZ with an insight into areas that have room for improvement. The 
study provides MCAZ with an insight into areas that have room for improvement. Current GMP Supervision of Manufactures and Inspections need 
to be upgraded; however, currently in Zimbabwe, there is inadequate internal audits, inadequate quality departments to do the validation and self-
inspection in pharmaceutical industries. The comparison results obtained showed grey areas needed to be enhanced by MCAZ.
Keywords: Marketing authorization, Medicines control authority of Zimbabwe, European medicines agency, Gap analysis, European medicines 
agency guidelines.
INTRODUCTION
Zimbabwe is a landlocked country located in the southern part of 
Africa. It is categorized under the low-to-middle income countries in 
the world. The national and health-care products in Zimbabwe are 
regulated by the medicines control authority of Zimbabwe (MCAZ). 
The MCAZ authority was first established in 1969 as the drug 
control council. Under the act of parliament, medicines and allied 
substances act (Chapter 15:03), the MCAZ became a successor of 
the Drug Control Council and Zimbabwe Regional Medicines Control 
Laboratory in 1997. The MCAZ reports to the Minister of Health and 
Child Welfare, but it has a 100% funding derived from fees collected 
for services. The MCAZ is responsible for ensuring that all medicines 
available for sale to the public of Zimbabwe are safe, effective, and 
of good quality. This authority will ensure that every medicinal 
product that needs to be marketed in Zimbabwe is registered first 
before it is distributed to the public. The evaluation and registration 
division (EVR) is designated to assess the applications for medicinal 
products [1].
The MCAZ is one of Africa’s triumph stories regarding the regulation of 
medicines and many other health products. In 2012, the MCAZ received a 
certification from the WHO prequalification program which has led to the 
expansion and improvement of MCAZ serves in the chemistry laboratory. 
The quality testing of medicinal products at MCAZ has proved to meet 
international standards. The MCAZ has supplementary advanced into a 
service provider for a number of countries in the African region such as 
Tanzania, Zambia, Ethiopia, Mozambique, and several others [2].
The MCAZ is one of the founding member states of the Southern African 
Development Committee (SADC) which is known as ZAZIBONA. This is 
a centralized procedure in which the objective is to provide access to 
safe, effective, and quality medicines by work sharing in the analysis 
of applications for registration. This centralized procedure allows 
inspection of manufacturing testing facilities. The aim is to allow 
a region which issues good-quality medicines to the public all the 
time and to significantly decrease the time taken for the approval of 
marketing authorization in individual countries. They also guarantee 
efficient utilization of resources within the regional regulatory by 
sharing their work and evaluations.
However, MCAZ still has a long way to go to meet the world international 
market of medicinal products. Stringently regulated countries such 
as the European Union (EU) have set a standard for the marketing and 
authorization of medicinal products in the world. EU is a giant in the 
drug regulating markets; it has very stringent requirements for drug 
development, drug processing, and drug approval. The Medicines Agency 
(EMA) is a decentralized body of EU which is in charge for the safety and 
promotion of public health and animal health, through the evaluation and 
supervision of medicines for human and veterinary use. The EMA was 
established in 1995 and has worked across EU and globally to facilitate 
public and animal health assessing medicines to severe scientific standards 
and by providing partners with independent science-based data. The 
main objective of the EU pharmaceutical legislation is to safeguard public 
health while protecting free movement of medicinal products [3].
The EMA is accountable for the assessment of applications for European 
marketing authorization for medicinal products (centralized procedure). 
In this centralized procedure, companies must succumb a single 
marketing authorization application to the EMA which will constantly 
monitor the safety of medicines through a pharmacovigilance program.
The EMA will take appropriate action if adverse drugs report suggests 
changes to the benefit-risk balance of a medicinal product [3].
MATERIALS AND METHODS
Registration requirements in EU
For a medicinal product to be placed on the market in Europe, a 
marketing authorization has to be issued by the competent authorities 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Contents EU Zimbabwe
Authority EMA MCAZ
Committees 1.Committee for human 
medicinal products
2.Pediatric committee




5.Committee for advanced 
therapies
6.Committee for orphan 
medicinal products
7.Committee for medicinal 
















2.The WHO collaborative 
procedure
3.ZAZIBONA procedure








1.New chemical entity 
application (biological and 
biosimilar medicines are 




CTD presentation eCTD Paper CTD
eCTD year implemented 2005 Not yet
Fees structure marketing authorization 
application
€282,100 for the whole 
process
$3000 for NCE registration 
$2 500 generics $1 500 
line extensions
Stability requirements
Number of batches 2 3
Climatic zone Northern Europe Zone I
Southern Europe Zone II
Zone II
Storage conditions long-term intermediate 
accelerated
25°C±2°C/60% RH±5% RH or 
30°C±2°C/65% RH±5% RH 12 
months
30°C±2°C/65% RH±5% RH 6 
months
40°C±2°C/75% RH±5% RH 6 
months
25°C±2°C/60% RH±5% 
RH or 30°C±2°C/65% 





Container closure system Testing to be conducted on 
the dosage form packaged in 
a container closure system 
proposed for marketing
Testing is done in dosage 
form packaged in the 
container closure system 
for marketing
Quality personnel certification Required May not be necessary
Bioequivalence requirements
Clinical research organization Audited EMA Audited MCAZ
Fasted/fed As recommended by EMA As recommended by MCAZ
Number of subjects Minimum 12 Minimum 12
1. Acceptance criteria for bioequivalence
2. Acceptance criteria for bioequivalence 
for special class drugs
90% confidence interval
80–125% Cmax 80–125% Cmax




Supporting documents ICH E3 Guidelines ICH E3 Guidelines
Manufacturing and control requirements
Number of batches 3 3
Packaging A minimum of 100,000 units 100,000
Batch size A minimum of 100,000 units 100,000
Finished product control requirements
Color identification Required needed
Disintegration Required Required
Water content Not required Required
Supporting documents ICH Q6A WHO TRS 95,2009
EMA: European medicines agency, MCAZ: Medicines control authority of Zimbabwe
Table 1: Comparison for EMA and MCAZ
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of the member state to the applicant. The legal requirements and 
procedures for making an application for a marketing authorization are 
outlined in Directive 2001/83/EC and in Regulation (EC) No726/2004. 
There are four marketing authorization procedures in EU which are the 
centralized procedure, decentralized procedure, mutual recognition, 
and national procedure. The centralized procedure is the authorization 
of medicines, whereby a single application, a single assessment and 
a single approval throughout the EU. This type of procedure enables 
the applicant to market the medicinal product and make it available 
to patients and health-care professionals all over Europe because of a 
single marketing authorization [4].
Mutual recognition procedure is when the applicant gets marketing 
authorization in several member states where the medicinal product 
in question has already received a marketing authorization from one 
of the member state at the time of application. After the first marketing 
EU MCAZ 
i.	 Administrative	information	such	as	cover	letter	specified	
for the particular country, application form applicable 
in that country, exclusivity statement, proof of payment 
to clinical investigators, proof of establishment of the 
applicant in EEA
Administrative information correspondence table of 
contents (M1–5) administrative information product 
information specific requirements proof of payment and 
regional summaries
ii. A4 (8.27×11.69 inches) paper size is used for the dossier 
preparation with font size 12 in Times New Roman
Similar to EU
iii. 1.3 Product information SPC (summary of product 
characteristic) is provided about the drug product in 
labeling
iv. 1.3.1. Mock-ups and specimens of labels and cartons sent 
with the application as appropriate. Braille is used for the 
labeling conditions on the labels
SPC, package inserts, patient information leaflet are 
provided in the labeling braille labeling not required
v. 1.4 Information about experts who sign the 
module 2 summaries. A qualified personnel is selected
Any member of the MCAZ is selected
vi.	 1.5	 Specific	 requirements	 for	 different	 kinds	 of	
applications (summary to support generics, hybrid, 
bibliographic, extension)
vii. Request for waiver is not provided in module 1.
No specific requirements biowaiver request is provided in 
module 1 in 1.2.8
viii.	1.6	 Environ	 risk	 certification	 21	 is	 given	with	 the	
information for GMO or Non-GMO. The fresh/new 
certificate	is	provided
No GMO or Non-GMO certification
ix. 1.7 information relating to orphan market exclusivity
x. 1.8 Data associated with pharmacovigilance. A separate 
additional section is provided for the pharmacovigilance 
system for surveying and controlling the post-approval 
undesired effects of the drug
xi. 1.9 Information relating to clinical trials
Evidence linking to an orphan drug is not required in this 
section
No information related to pharmacovigilance required in 
this module
Most generic drugs are registered in Zimbabwe. Clinical 
trials information is obtained from MCAZ
Module 2: It is the same for EU and MCAZ
Module 3: Quality
i. 3.2. S drug substance data may be submitted as an EU part 
DMF (open part to be reproduced in 3.2. S) or as a reference 
to	pharmacopeia	European	certificate	of	suitability,	for	an	
EU monograph substance
Drug substance data are submitted to the MCAZ in the form 
of DMF and QIS with reference of the pharmacopeias used. 
A complaint has been already raised.
i. 3.2.S 7 stability storage requirements to be stated in accord 
with CHMP guideline
1.2 S7 stability
Storage requirements as per MCAZ quality guidelines
ii. 3.2. P description and composition colors to be on the 
European permitted list. Excipients to be designated as 
conforming to European national pharmacopeia where 
there is a monograph 3.2 P 4 excipients to conform 
to European national pharmacopeia if described in a 
monograph.
iii. 3.2.P 5 Control of drug product
Assay	limits	to	be	̀ 5%	unless	justified.	A	different	manufacturer	
and	shelf‑life	specification	may	be	required	for	products	
to conform to the general monograph of the European.
3.2 P Reference may be in DMF supplied directly to MACZ 
by excipient and container closure manufacture
3.2 P 1 Description and composition. Colors to be on MCAZ 
permitted list. Excipients to be designated as confirm to 
monograph.
1.3	 P	4	Excipients	to	confirm	to	MCAZ	guidelines
3.2 P 5 control of drug product
Assay±10%. A single regulatory shelf specification is 
allowed
iv. 3.2 P 7 Container closure system
Name of the manufacturer not required unless a product is 
critical (e.g., parental).
v. 3.2 P 8 Stability
Storage requirements in accord with CHMP guidelines
3.2.P 7 Container closure system
As per MCAZ quality guidelines
3.2 P 8 Stability
Stability storage requirements to be in accord with MCAZ 
requirements
Module 4: There are no major differences in this module.
Module 5
Module 2.3 quality overall summary and module 2.5 clinical 
overview summarize this module
Module 5
It also includes a summary of module 2.3 quality overall 
summary and module 2.5 clinical overview.
MCAZ: Medicines control authority of Zimbabwe, EU: European Union
Table 2: Summary of key national differences
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authorization in the community is granted, the marketing authorization 
holder may request one or more member state to recognize an 
authorization granted by the reference member state by submitting an 
application in accordance with article 28 of Directive 2001/83/EC. The 
reference member state will provide a list of documents to the concerned 
member state and applicant which will be validated in 90 days. The 
documents to be submitted include the assessment report, summary 
product of characteristics, labeling, and package leaflet. The concerned 
member state shall assess and approve these documents and inform the 
reference member state (Kumar, 2015).
The decentralized procedure is whereby an applicant obtains a 
marketing authorization in several member states where the medicinal 
product in question has not yet received a marketing authorization in 
any member state at the time of application. A national procedure is the 
starting point for mutual recognition and decentralized procedure, this 
procedure is when an applicant submits an application to an individual 
competent member state authority of the EU.
Centralized procedure in EU
Flowchart of centralized procedure show in Fig. 1.
Flowchart: Mutual recognition procedure show in Fig. 2.
Flowchart of decentralized procedure show in Fig. 3.
MCAZ
To obtain approval to market, sell, and distribute the medicinal product 
for human or animal use in Zimbabwe, an applicant should register 
with the Medicine Control Authority of Zimbabwe. The EVR of MCAZ 
is designated to assess the applications of medicinal products. This 
division is responsible for reviewing the safety, quality, and efficacy of 
medicines intended for marketing, sale, and distribution in Zimbabwe. 
There are three ways of obtaining marketing authorization in Zimbabwe. 
One is through the national procedure by MCAZ, second is by the WHO 
Collaborative Procedure, and third is by The ZAZIBONA procedure.
The WHO Collaborative Registration Procedure serves to expedite and 
fast-track registration of products which have already been assessed and 
prequalified by the WHO Prequalification team. In the ZAZIBONA process, 
it is a collaborative registration initiative among four national medicines 
regulatory authority in Zambia, Zimbabwe, Botswana, and Namibia. The 
objective of this procedure is to assist in the provision of good quality 
medicines through work sharing in the assessment of applications 
for registration and inspection of manufacturing and testing facilities. 
Medicinal products that pass the evaluation are then provided with an 
approval for marketing authorization in the participating countries in 
which applications for registration would have been submitted [5].
Flowchart medicinal product registration by MCAZ Show in Fig. 4.
A schematic overview of the collaborative registration procedure [6].
Zazibona process design
Criteria EMA MCAZ (WHO BA/BE guidelines)
API BCS Class I BCS Class III BCS Class I BCS Class II BCS Class III






that might affect the 
bioavailability and 
qualitative
An exhibit that the excipients are well established for use in products 
with API and will not lead to any differences with respect to process 
affecting the absorption or which may lead to interactions that affect the 
pharmacokinetics of API
Drug type It is not for narrow therapeutic index drugs Both indication and therapeutic index are important in determining the 
biowaiver based BCS can be applied
Dissolution 
formulation 








Rapid dissolution (NLT 
85% in 30 min)
Dose solubility 
ratio of<250 ml at 
pH 6.8 and rapid 
dissolution : (NTL 
85% in 30 min) at 
pH 6.8
Very rapid 
dissolution (>85% in 
within 15 min)
Comparative in vitro 
dissolution test
pH 1–6.8 (at least pH 1.2,4.5, and 6.8) no 
surfactant enzymes for gelatin only
pH 1.2, 4.5, and 6.8 
Equivalence 
acceptance criteria
Similarity (f2 calculation 50–100) or other 
appropriate statistical methods
Similarity (f2 calculation 50–100) or other appropriate statistical 
methods, provided that the same criterion is used for acceptance( 
maximum 10% differences between the profiles)
FDC FDC products might be acceptable if all API 
belong to BCS - Class I or III
FDC product with Class I, II, and III APIs meeting the dissolution criteria 
as specified above
FDC: Fixed dose combination, EMA: European medicines agency, MCAZ: Medicines control authority of Zimbabwe
Table 3: Summarized comparison of the Biowaiver requirements for EMA and MCAZ
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Comparison of CTD modules.
The Table 4 gives detailed information about procedures and timelines 
for variations in EU and Zimbabwe [7,8,9 and 10].
This study systematically challenges MCAZ regulatory requirements and 
procedures by comparing them with the EU standard drug regulations. It 
helps process improvement in Zimbabwe drug regulatory system [ 11]. This 
will enable the MCAZ to determine what actions are necessary for them to 
be in compliance with the new EU guidelines and requirements. The study 
provides MCAZ with an insight into areas that have room for improvement 
[ 12, 13, 14,15 ]. Current GMP Supervision of Manufactures and Inspections 
need to be upgraded. However, currently, in Zimbabwe, there are inadequate 
internal audits, inadequate quality departments to do the validation and 
self-inspection in pharmaceutical industries [ 16-40 ]. The MCAZ can 
resolve this by ensuring that pharmaceutical industries implement frequent 
inspections determined on risk-based approach as done in EU [ 41-56].
Braille requirement
In Zimbabwe, the MCAZ lacks in the area of braille labeling on drugs 
primary package. It can harmonize the braille requirements with that 
of EMA and address applicants to implement these necessities on the 
carton of a medicinal product [57-73].
Pharmacovigilance
A very big gap in this area underreporting of ADR due to common 





problem resulting in ignorance for ADR reporting.
Fig. 1: Centralized procedure
Fig. 2: Mutual recognition procedure
Fig. 3: Decentralized procedure
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rather than to let an applicant visit the MCAZ premises to collect the 
guidelines. The website must be updated on a daily bases. There is 
a gap in the capacity of assessing and registering new products and 
to carry clinical trials of new drugs for neglected diseases that are 
necessary to establish safety and efficacy in Zimbabwe. The SADC 
has pursued harmonization of registration procedures with a mutual 
recognition process akin to that of Europe. There is still a gap in the 
effort put by SADC in relation to focus on NCEs. The SADC should put 
more effort to harmonize formulation of NCEs rather than on generic 
products only [ 74-81].
CONCLUSION
EU with its communal and mutual recognition procedures to 
enable one dossier to oblige for all is a well-established exemplary 
for harmonization of drug registration. Thus, the MCAZ and SADC 
should correspond with EU guidelines to enable improvement 
of a common scientific framework for assessing medicines and 
safeguarding the legislation which is enacted to support the 
assessments. Harmonization of EU and SADC documentation will 
enable manufacturers to prepare the same dossier for each authority, 
although there are still country-specific requirements such as the 
product information documents. Registration of medicines needs to 
be vigorously embarked on by the MCAZ. Factors responsible for the 
small number of registered medicines need to be determined so that 
remedial action can be taken. Subsequently, Zimbabwe is resource 
constrained, allocation of information, and facilities to register 
medicines in the subregion must be stimulated. To address the human 
resources, restraints for MCAZ investment in the training of the human 
capital for efficient implementation of various functions of regulation 
should be mandatory. To ensure greater value for harmonization and 
benefits, the MCAZ and Zazibona member states should build capacity 
Europe (EMA) 




”Do&Tell” and do 
not require prior 
approval 
Notify within 




within 2 weeks of 
implementation
2.Type IB “Tell, Wait and Do” Agency will give a 
response within 
30 days
3.Type II Require 
approval before 
implementation and 
the variation has 
an effect on safety, 
efficacy, and quality.
Assessment period 
is 60 days it may 
be reduced or 
extended up to 
90 days, based on 
the urgency of the 
matter
4.Extensions These notifications 
will be evaluated as 
an initial MAA.
It may be 
considered 




Type of application Procedure Timeline




subject to MCAZ 
response 
2.Major variation. MCAZ evaluates Within duration 
subject to MCAZ 
response
EMA: European medicines agency, MCAZ: Medicines control authority of 
Zimbabwe, EU: European Union
Thus, to stimulate the reporting system in Zimbabwe, there should 
be easy access to reporting forms and other means of reporting. 
There should be public education regarding adverse drug reaction 
reporting as this is done in EU, it helps the public to be aware of ADR. 
(ATUL KHURANA, 2014) MCAZ PVCT team can establish a mobile 
application in which health-care professionals and consumers can 
report ADR.
Digitalization
There is a huge gap in the online application for a marketing 
authorization in Zimbabwe by the regulatory authority of MCAZ. 
MCAZ should harmonize their webpage with that of EMA. All 
important documents should be easily accessed on the website, 
for example, the GMP guidelines must be available on the website 
90 days
Applicant Submits applicaon 
to Director- General
Applicant Pays the Prescribed 
Fees











allocates a registered 
number MCAZ Nofy the 
applicant in wring 
MCAZ Nofy the 
applicant in wring 
Applicant Re- submit
Fig. 4: Medicinal product registration by MCA
Table 4: Comparisons of variations in EU and Zimbabwe
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for better sharing of resources. To strengthen WHOPQP programs, 
tolerable funding is required to support operations and regional 
activities. Consequently, Government should offer an adequate grant 
to support program implementation by MCAZ; the manufacturing 
pharmaceuticals should access and use most of the industry fees for 
production of new drugs.
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